Daewoong Pharmaceutical has signed an agreement with Cooper Pharma for the licence and distribution of their potassium-competitive acid blocker (P-CAB) drug, Fexuprazan, for the improvement of digestive health in Morocco.
As per the agreement, Fexuprazan is scheduled to be locally released in the Moroccan market in 2025. The partnership agreement between Daewoong Pharmaceutical and Cooper Pharma is valued at approximately USD 20.32 million (equivalent to KRW 27 billion).
Through this strategic partnership, Daewoong Pharmaceutical aims to expand the presence of Fexuprazan in Africa, capitalising on its unique properties and efficacy in managing GERD. This move represents an important milestone for both the parties, potentially benefiting patients in Morocco and contributing to the advancement of digestive health solutions in the region.
Fexuprazan is known for its rapid and consistent suppression of gastric acid, regardless of food intake. Additionally, it boasts the longest half-life of 9 hours among P-CABs, providing a longer duration of action compared to other drugs used for GERD treatment.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!